Skip to content

Biomarkers in Atopic Dermatitis and Psoriasis The Netherlands

Biomarkers in Atopic Dermatitis and Psoriasis The Netherlands - BIOMAP NL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON48036
Enrollment
110
Registered
2019-09-23
Start date
2020-06-16
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis atopic eczema

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with atopic dermatitis participating in the TREAT NL registry. Patients can be part of the TREAT NL registry if they have atopic dermatitis AND start with a systemic immunomodulating treatment or phototherapy in the context op standard patient care

Exclusion criteria

Exclusion criteria: No participation in the TREAT NL registry, patients not recieving systemic immunomodulating treatment or phototherapy as treatment for their eczema

Design outcomes

Primary

MeasureTime frame
The combined efforts of BIOMAP will support the definition of endotypes, i.e. a more precise disease classification, a definition of biomarkers enabling patient stratification and patient-directed care strategies, and the early identification of the most suitable therapy for every patient.

Secondary

MeasureTime frame
BIOMAP will also stimulate future research on mechanisms and innovative treatments directed at endotype components.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)